Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: satish kamat who wrote (380)	2/14/2000 8:31:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

<<What frustrates me is the companys' inability to disseminate meaningful progress info. into the street. >> It is embarrassing that Company of their SIZE and CAPACITY have so conservative approach with street and analysts. Recently they did upgrade web site, so there is trend toward better relation with street. However we need more detailed info. Also from today news on angiogenesis: biz.yahoo.com <<Based on original research conducted in collaboration with consumer and marketing leader Procter & Gamble, the 2000 Market Study and Analysis was produced by Angiogenesis Foundation analysts, with expert contributions from leaders in academia, industry and governmental agencies.>> So, P&G WAS and IS very interested in small molecule Tie-2 receptor agonist/antagonist. They (REGN-P&G) are doing some screening. No idea where are they now? To bad that P&G give up so easily in battle with PFE over WL/AHP. Miljenko